Decoy Therapeutics (NASDAQ:DCOY) Sees Significant Drop in Short Interest

Decoy Therapeutics (NASDAQ:DCOY) was the recipient of a large decrease in short interest during the month of June. As of June 15th, there was short interest totaling 1,966 shares, a decrease of 78.5% from the May 31st total of 9,158 shares. Based on an average daily volume of 18,536 shares, the short-interest ratio is currently 0.1 days. Approximately 0.4% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Decoy Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, June 12th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Decoy Therapeutics has a consensus rating of “Hold” and an average target price of $30.00.

Decoy Therapeutics Stock Performance

NASDAQ DCOY traded down $0.40 on Friday, reaching $5.52. 5,227 shares of the stock traded hands, compared to its average volume of 13,592. The stock’s fifty day moving average price is $6.12. The company has a market capitalization of $2.94 million, a P/E ratio of -0.05 and a beta of 0.57. Decoy Therapeutics has a 12 month low of $4.32 and a 12 month high of $415.80.

Decoy Therapeutics (NASDAQ:DCOY) last posted its quarterly earnings data on Friday, May 8th. The company reported ($4.18) EPS for the quarter. Research analysts predict that Decoy Therapeutics will post -12.97 earnings per share for the current fiscal year.

Decoy Therapeutics Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.